Sanofi wins FDA nod for injectable multiple myeloma therapy

Seeking Alpha ·

Sanofi ( SNY ) on Friday announced FDA approval of a subcutaneously delivered version of its multiple myeloma therapy Sarclisa, which is currently available as an intravenous formulation in the U.S. The new formulation, branded as Sarclisa Escena, will therefore be indicated in the

DYAX Investor Sentiment

Bullish (Long) 50% · Bearish (Short) 50%

590 participants

Related News

원문 보기 — Seeking Alpha